Observational studyDrug design, development and therapy2026
An Immune Model Incorporating NK Cells and IL-12 to Predict the Efficacy of the Initial Treatment Cycle of Efgartigimod in Generalized Myasthenia Gravis.
Observational study in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Efgartigimod (EFG), a neonatal Fc receptor (FcRn) antagonist for generalized myasthenia gravis (gMG), exhibits variable treatment responses. This study aimed to investigate the associations of baseline clinical characteristics and multidimensional immune profiles with the clinical response to EFG in patients with acetylcholine receptor antibody-positive (AChR+) gMG, and develop a predictive model. Methods: This multicenter retrospective observational study enrolled 35 AChR+ gMG patients who received at least one cycle of EFG. Responders were defined as those achieving a Myasthenia Gravis Activities of Daily Living (MG-ADL) score reduction of ≥ 2 points that was sustained for ≥ 1 month. After univariable screening, three models (Clinical, Immune, Integrated) were constructed using a complete-case modeling subset of 26 patients via multivariable logistic regression, least absolute shrinkage and selection operator (LASSO), and random forest algorithms. The optimal model was selected via leave-one-out cross-validation (LOOCV) and translated into a clinical risk score and an online calculator. Results: Among 35 patients, 25 responded (68.6%). Non-responders had significantly higher baseline NK cell counts ( Conclusion: Baseline NK cell counts and IL-12p70 levels may predict EFG response in AChR+ gMG. The dual-biomarker Immune Model demonstrates robust performance, and has been translated into an online tool but yet requires validation in prospective, larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.